A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs Brepocitinib (Primary) ; PF 6651600 (Primary)
- Indications Vitiligo
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 24 Jul 2019 Planned End Date changed from 7 Dec 2020 to 14 Dec 2020.
- 24 Jul 2019 Planned primary completion date changed from 15 Jun 2020 to 14 Dec 2020.
- 29 Apr 2019 Planned End Date changed from 17 Mar 2021 to 7 Dec 2020.